Alcon, Bausch + Lomb April Rx Trends: Needham Insights

Key Prescription Data Released

Needham has released its analysis of April prescription data for key eye care medications from Alcon and Bausch + Lomb, based on IQVIA tracking. The report highlights significant shifts in the dry eye market and mixed performance for glaucoma treatments.

Company Performance Overview

For Alcon, several products saw year-over-year declines, including Rhopressa down 9% and Eysuvis down 10%. Pataday prescriptions saw a modest 1% increase. In contrast, Bausch + Lomb experienced strong growth with Miebo prescriptions jumping 31% year-over-year, while its Xiidra prescriptions fell 12%.

Market Share Impact

The prescription trends directly impacted market positioning. Bausch + Lomb's total share of the dry eye prescription market increased to 49.5% at the end of April, up from 48.4% the previous month. Alcon's share in the same category remained stable at 3.0%.

Summary

The April data suggests Bausch + Lomb is strengthening its position in the dry eye market, driven by Miebo's robust performance. Alcon faces headwinds with several key drugs, and investors will be watching to see how the company responds to these competitive pressures.

FAQ

Q: Which Bausch + Lomb drug performed best in April?
A: Miebo was the top performer, with prescriptions increasing 31% year-over-year.

Q: What was Alcon's overall dry eye market share?
A: Alcon's total dry eye prescription share was unchanged at 3.0% at the end of April.

Source: Investing.com